Literature DB >> 19370899

Reduction of postmolar gestational trophoblastic neoplasia by early diagnosis and treatment.

Alon Ben-Arie1, Hagit Deutsch, Vania Volach, Gil Peer, Monica Husar, Ofer Lavie, Ofer Gemer.   

Abstract

OBJECTIVE: To compare contemporary and historical clinical presentation of complete moles (CMs) and the rates of gestational trophoblastic neoplasia (GTN). STUDY
DESIGN: A study was conducted of a current cohort of 108 consecutive cases of CM from 3 medical centers in Israel accrued during a 5-year period and 87 CM cases reported by the New England Trophoblastic Disease Center (NETDC) from the years 1988 to 1993. Clinical presentation and the rate of GTN of our cohort of CM and cases from the NETDC were compared.
RESULTS: Fewer current CMs presented with vaginal bleeding than historic NETDC cases (52% vs. 84%, p <0.001, respectively), and a greater proportion of current patients with CM were referred to termination of the pregnancy due solely to ultrasonographic findings (38% vs. 9%, p < 0.001, respectively). GTN rates were significantly lower in the current patients with CM compared to NETDC controls (14% vs. 23%, p<0.05, respectively).
CONCLUSION: First-trimester ultrasound examination leads to early diagnosis of molar and of nonviable pregnancies subsequently histologically diagnosed as CM. The early evacuation of the molar pregnancy is associated with a reduction in the rate of GTN.

Entities:  

Mesh:

Year:  2009        PMID: 19370899

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  2 in total

1.  Hydatidiform mole in Jos, Nigeria.

Authors:  Amaka N Ocheke; Jonah Musa; Alexander O Uamai
Journal:  Niger Med J       Date:  2011-10

2.  Clinico-epidemiological profile of molar pregnancies in a tertiary care centre of Eastern Nepal: a retrospective review of medical records.

Authors:  Nimisha Agrawal; Reshu Agrawal Sagtani; Shyam Sundar Budhathoki; Hanoon P Pokharel
Journal:  Gynecol Oncol Res Pract       Date:  2015-10-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.